Skip to content

Safety on Switching Between Different Botulinum Toxin-A

Switching Between Different Types of Botulinum Toxin-A in Children With Cerebral Palsy Treated for Spasticity: a Safety Retrospective Evaluation

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03234413
Enrollment
118
Registered
2017-07-31
Start date
2017-07-30
Completion date
2017-11-30
Last updated
2018-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral Palsy

Keywords

Botulinum Toxin-A

Brief summary

Clinical guidelines recommend the use of Botulinum Toxin-A (BoNT-A) for localized/segmental spasticity in children with cerebral palsy. At the Kocaeli University (KOU) Department of Physical Medicine and Rehabilitation (PMR) more than 800 patients have been injected with the two approved toxinA types; OnabotulinumtoxinA or AbobotulinumtoxinA. With this study investigators would like to evaluate retrospectively if switching from one toxin to another is safe as well as to evaluate if the efficacy when switching from one toxin to another was maintained.

Detailed description

A data base was designed to capture all data that were considered relevant to the treatment evaluation. The data were transcribed directly from participants medical records. For the purpose of the study, data from the two subsequent visits where a different type of toxin was given will be collected and evaluated . In order to collect the pre and post status in terms of safety and efficacy, for each participant, data corresponding to the 6 previous and posterior months after the switch of the toxin will also be collected or data corresponding to the previous and posterior visit after the switch of the toxin will also be collected.

Interventions

DRUGBotulinum toxin type A

Botulinum toxin type A

Sponsors

Nigar Dursun
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
2 Years to 18 Years

Inclusion criteria

* children diagnosis of cerebral palsy with respect to Rosenbaum criteria, * children having received repeated injections with two different types of toxinA treatment into their lower limb(s)

Exclusion criteria

* children without repeated Botulinum toxin type A injections * children having received repeated injections with same type of toxinA

Design outcomes

Primary

MeasureTime frameDescription
Occurence of treatment related adverse eventsUp to 30 monthsOverall and per injection cycle

Secondary

MeasureTime frameDescription
Modified Ashworth ScaleUp to 30 monthsSpasticity Assessment Scale
Tardieu ScaleUp to 30 monthsSpasticity Assessment Scale
Observational Gait ScaleUp to 30 monthsGait Assessment Scale

Other

MeasureTime frameDescription
Goal Attainment ScaleUp to 30 monthsOutcome measure for goal selection and goal scaling

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026